Hemodynamic and beta-adrenergic receptor adaptations during long-term beta-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol, and propranolol in hypertensive patients.

In an attempt to further clarify the mechanism of the maintenance of the antihypertensive effect of beta-adrenoceptor antagonists, the effects of four antagonists with different ancillary properties (acebutolol, atenolol, pindolol, and propranolol) on systemic and renal hemodynamics, body fluid volumes, hormones, and lymphocyte beta-adrenoceptor density were studied in four groups of 10 hypertensive patients. The patients were observed for 3 weeks during active treatment and for 2 weeks after withdrawal of treatment. At the end of the 3-week treatment period, the four drugs had an equal antihypertensive effect (fall in mean arterial pressure, 10-13%). Although renin activity was suppressed (60-70%) by all four drugs, changes in renin or pretreatment values of renin levels were not correlated with the fall in blood pressure. The drugs had no effect on plasma catecholamine concentrations or body fluid volumes. Despite similar antihypertensive effects among the four drugs, the changes in flow and resistance underlying the fall in blood pressure differed considerably. With pindolol, the fall in blood pressure was associated with a fall in vascular resistance (26 +/- 6%), whereas with propranolol, it was predominantly associated with a fall in cardiac output (11 +/- 7%). No significant changes in vascular resistance or cardiac output occurred with atenolol or acebutolol. The changes in renal blood flow and renal vascular resistance occurred in parallel with the changes in cardiac output and systemic vascular resistance. Plasma epinephrine concentration and pretreatment cardiac chronotropic responsiveness to isoproterenol appeared to be inversely correlated with lymphocyte beta-adrenoceptor density (Bmax) (r = -0.41 and -0.43, respectively). With pindolol, Bmax decreased maximally by 39 +/- 6%, and with propranolol, it increased by 51 +/- 17%. With both drugs, significant changes in Bmax were already present 24 hours after treatment. Furthermore, 1 week after withdrawal of treatment with pindolol, Bmax was still down-regulated, and cardiac chronotropic responsiveness was still decreased, whereas 1 week after withdrawal of propranolol, Bmax was still up-regulated, and cardiac chronotropic responsiveness was still increased. No changes in Bmax occurred with the beta 1-selective antagonists acebutolol and atenolol. Thus, despite an equal antihypertensive effect, the four beta-adrenoceptor antagonists appear to have dissimilar effects on cardiac output, renal blood flow, and lymphocyte beta-adrenoceptors. Changes in cardiac output, the circulating blood volume, or angiotensin-mediated vasoconstriction are factors unlikely to be crucial for the antihypertensive effect of beta-adrenoceptor antagonists. Therefore, interference with vasoconstrictor nerve activity through blockade of either central or peripheral prejunctional beta-adrenoceptors could be an alternative explanation of their blood pressure-lowering potential.

[1]  A. J. Man in 't Veld,et al.  Hemodynamic and hormonal adaptations to beta-adrenoceptor blockade. A 24-hour study of acebutolol, atenolol, pindolol, and propranolol in hypertensive patients. , 1988, Circulation.

[2]  P. Cryer,et al.  Direct relationship between mononuclear leukocyte and lung beta-adrenergic receptors and apparent reciprocal regulation of extravascular, but not intravascular, alpha- and beta-adrenergic receptors by the sympathochromaffin system in humans. , 1988, The Journal of clinical investigation.

[3]  F. Boomsma,et al.  EFFECT OF UNNATURAL NORADRENALINE PRECURSOR ON SYMPATHETIC CONTROL AND ORTHOSTATIC HYPOTENSION IN DOPAMINE-BETA-HYDROXYLASE DEFICIENCY , 1987, The Lancet.

[4]  S. Jamieson,et al.  β1‐ and β2‐Adrenergic‐Receptor Subpopulations in Nonfailing and Failing Human Ventricular Myocardium: Coupling of Both Receptor Subtypes to Muscle Contraction and Selective β1‐Receptor Down‐Regulation in Heart Failure , 1986 .

[5]  M. Schalekamp,et al.  Chronic Effect of Ketanserin in Mild to Moderate Essential Hypertension , 1986, Hypertension.

[6]  P. Molinoff,et al.  Effects of pindolol and propranolol on beta adrenergic receptors on human lymphocytes. , 1986, The Journal of pharmacology and experimental therapeutics.

[7]  P. Molinoff,et al.  Coexistence of beta-1 and beta-2 adrenergic receptors in the human heart: effects of treatment with receptor antagonists or calcium entry blockers. , 1985, The Journal of pharmacology and experimental therapeutics.

[8]  F. Derkx,et al.  Splint renal function after captopril in unilateral renal artery stenosis. , 1984, British medical journal.

[9]  R McCarty,et al.  Relationship between plasma norepinephrine and sympathetic neural activity. , 1983, Hypertension.

[10]  R. S. Williams,et al.  Differentiation of Hemodynamic, Humoral and Metabolic Responses to β1‐ and β2‐adrenergic Stimulation in Man Using Atenolol and Propranolol , 1983 .

[11]  J. Sowers,et al.  Acute changes in noradrenaline levels do not alter lymphocyte beta-adrenergic receptor concentrations in man. , 1983, Cardiovascular research.

[12]  A. J. Man in 't Veld,et al.  Asynchronous changes in prorenin and renin secretion after captopril in patients with renal artery stenosis. , 1983, Hypertension.

[13]  M. Schalekamp,et al.  Effects of 10 Different β‐Adrenoceptor Antagonists on Hemodynamics, Plasma Renin Activity, and Plasma Norepinephrine in Hypertension: The Key Role of Vascular Resistance Changes in Relation to Partial Agonist Activity , 1983, Journal of cardiovascular pharmacology.

[14]  B. Tomlinson,et al.  The effect of intrinsic sympathomimetic activity on beta-receptor responsiveness after beta-adrenoceptor blockade withdrawal. , 1982, British journal of clinical pharmacology.

[15]  A. J. Man in 't Veld,et al.  How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism. , 1982, British journal of clinical pharmacology.

[16]  B. J. Clark,et al.  Pindolol--the pharmacology of a partial agonist. , 1982, British journal of clinical pharmacology.

[17]  H J Motulsky,et al.  Adrenergic receptors in man: direct identification, physiologic regulation, and clinical alterations. , 1982, The New England journal of medicine.

[18]  G. Jennings,et al.  Effect of propranolol on noradrenaline kinetics in patients with essential hypertension. , 1981, British journal of clinical pharmacology.

[19]  O. Hartling,et al.  Adrenergic beta receptor blockade: Hemodynamic importance of intrinsic sympathomimetic activity at rest , 1981, Clinical pharmacology and therapeutics.

[20]  R. Rizza,et al.  Epinephrine and norepinephrine are cleared through beta-adrenergic, but not alpha-adrenergic, mechanisms in man. , 1980, Metabolism: clinical and experimental.

[21]  Perry,et al.  Elevation of beta-adrenergic receptor density in human lymphocytes after propranolol administration. , 1980, The Journal of clinical investigation.

[22]  W. MacIntyre,et al.  Automated computer program for radionuclide cardiac output determination. , 1979, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  D. Shand,et al.  Proposed mechanisms of propranolol's antihypertensive effect in essential hypertension. , 1976, The New England journal of medicine.

[24]  P. Lund-johansen Haemodynamic long-term effects of a new beta-adrenoceptor blocking drug, atenolol (ICI 66082), in essential hypertension. , 1976, British journal of clinical pharmacology.

[25]  T. Goodwin,et al.  The effect of pindolol on plasma renin activity and blood pressure in hypertensive patients. , 1976, British journal of clinical pharmacology.

[26]  A. Amery,et al.  Mechanism of hypotensive effect during betaadrenergic blockade in hypertensive patients. , 1976, American heart journal.

[27]  D. Warren,et al.  Deterioration in Renal Function after Beta-blockade in Patients with Chronic Renal Failure and Hypertension , 1974, British medical journal.

[28]  M. Weber,et al.  β-Blockers and Plasma Renin Activity in Hypertension , 1974 .

[29]  J. Laragh,et al.  Antihypertensive action of propranolol. Specific antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. , 1973, The American journal of cardiology.

[30]  W. Birkenhäger,et al.  Abnormal renal haemodynamics and renin suppression in hypertensive patients. , 1970, Clinical science.

[31]  A. Bøyum,et al.  Isolation of mononuclear cells and granulocytes from human blood. , 1968 .

[32]  A. Grollman,et al.  An evaluation of radiosulfate for the determination of the volume of extracellular fluid in man and dogs. , 1953, The Journal of clinical investigation.

[33]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[34]  G. Scatchard,et al.  THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS , 1949 .